CN116350676A - Medicine for promoting periodontal bone reconstruction by stem cell exosome - Google Patents
Medicine for promoting periodontal bone reconstruction by stem cell exosome Download PDFInfo
- Publication number
- CN116350676A CN116350676A CN202310359219.XA CN202310359219A CN116350676A CN 116350676 A CN116350676 A CN 116350676A CN 202310359219 A CN202310359219 A CN 202310359219A CN 116350676 A CN116350676 A CN 116350676A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- extract
- solution
- bone
- periodontal bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 68
- 210000001808 exosome Anatomy 0.000 title claims abstract description 61
- 230000003239 periodontal effect Effects 0.000 title claims abstract description 48
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 230000001737 promoting effect Effects 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title description 14
- 239000000411 inducer Substances 0.000 claims abstract description 56
- 239000000284 extract Substances 0.000 claims abstract description 34
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 14
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 14
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 6
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 6
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 6
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 46
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 23
- 239000001963 growth medium Substances 0.000 claims description 21
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 16
- 239000005720 sucrose Substances 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000004113 cell culture Methods 0.000 claims description 13
- 229940036811 bone meal Drugs 0.000 claims description 12
- 239000002374 bone meal Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims description 8
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- 210000005258 dental pulp stem cell Anatomy 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 235000020737 peppermint extract Nutrition 0.000 claims description 6
- 230000010072 bone remodeling Effects 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 239000000469 ethanolic extract Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 102100025222 CD63 antigen Human genes 0.000 claims description 3
- 102100027221 CD81 antigen Human genes 0.000 claims description 3
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 3
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims description 3
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 claims description 3
- 241000219780 Pueraria Species 0.000 claims description 3
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 23
- 230000004069 differentiation Effects 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 7
- 230000011164 ossification Effects 0.000 abstract description 5
- 210000002449 bone cell Anatomy 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 14
- 210000004195 gingiva Anatomy 0.000 description 14
- 238000004140 cleaning Methods 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 229940124599 anti-inflammatory drug Drugs 0.000 description 8
- 201000001245 periodontitis Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 240000002853 Nelumbo nucifera Species 0.000 description 6
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 6
- 241000893536 Epimedium Species 0.000 description 5
- 235000006679 Mentha X verticillata Nutrition 0.000 description 5
- 235000002899 Mentha suaveolens Nutrition 0.000 description 5
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 5
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 5
- 235000018905 epimedium Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940105902 mint extract Drugs 0.000 description 3
- 230000009818 osteogenic differentiation Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000003921 particle size analysis Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 206010072574 Periodontal inflammation Diseases 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 210000004489 deciduous teeth Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 235000020696 epimedium extract Nutrition 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of high-efficiency osteogenesis, in particular to a medicament for promoting periodontal bone reconstruction by utilizing stem cell exosomes, which can effectively enhance the bone differentiation of periodontal bone cells by adding the odontogenic exosomes on the basis of original grinding medicaments, and in addition, the extract of kudzuvine root and the extract of peppermint are screened from a plurality of reported traditional Chinese medicines with osteogenesis differentiation, and according to the research of clinical cases, the extract can effectively promote the regrowth of cementum wires, increase bone level and recover bone trabeculae, and can increase the bone level by more than 4.0mm after reasonable proportion of the two inducers, compared with the prior art, the medicament has better effect in 3.0mm improvement, and better effect in periodontal bone reconstruction medicaments.
Description
[ field of technology ]
The invention relates to the technical field of efficient bone formation, in particular to a medicament for promoting periodontal bone reconstruction by utilizing stem cell exosomes.
[ background Art ]
Periodontitis is a chronic inflammation that invades the gums and periodontal tissues, a destructive disease characterized mainly by the formation of periodontal pockets and inflammation of the pocket walls, periodontal bone loss, a group of characteristics of dental loosening, malignant diseases of the oral cavity, applicant's prior application patent: 202110311551.X proposes the use of mesenchymal stem cell gel, allogeneic bone powder and inducer for the preparation of a medicament for the reconstruction of periodontal bone, however, the specific inducer composition is not clear.
In intensive researches of the applicant, it is found that although mesenchymal stem cell gel can promote bone differentiation of cells, impurities in the mesenchymal stem cell gel are still more, bone differentiation effect is not optimal, peripheral bone heightening effect is not optimal, certain traditional Chinese medicines reported in the prior art have the effects of tonifying kidney and strengthening yang, strengthening tendons and bones, dispelling wind and removing dampness, pharmacological and clinical researches prove that the mesenchymal stem cell gel has good effects of preventing and treating osteoporosis, can promote osteoblast proliferation and mineralization and inhibit osteoclast activity, and the traditional Chinese medicine components can be used as inducers of medicines, however, in specific researches, it is found that part of the traditional Chinese medicine preparations have obvious inhibition effect on cell proliferation, inhibition effect even leads to bone cell growth not to be good, and in addition, inducer with the effect of promoting bone differentiation is reported to have promotion effect, some have even inhibition effect in periodontal bone reconstruction process, so that the screening of the inducer is particularly important in the medicines.
[ invention ]
In view of the foregoing, there is a need for screening and research on inducers that are effective in promoting the application of mesenchymal stem cells in the preparation of periodontal bone reconstruction drugs.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
a medicament for promoting periodontal bone reconstruction by utilizing stem cell exosomes, which comprises the following components in percentage by mass: 15% of mesenchymal stem cell gel, 4% of odontogenic stem cell exosomes, 80% of bone meal and 1% of inducer; the inducer is radix Puerariae extract and/or herba Menthae extract.
Furthermore, the kudzuvine root extract and the mint extract are ethanol extracts.
Further, the ethanol of the ethanol extract is 70% ethanol solution by volume.
Further, the mass ratio of the kudzuvine root extract to the peppermint extract is 1:3.
Further, the specific extraction method of the kudzuvine root extract and the peppermint extract comprises the following steps: 500g of dry kudzuvine root, dry epimedium herb, fresh peppermint and fresh lotus leaf medicinal materials are respectively weighed, and are refluxed for 2 times with ethanol solution with the volume percentage of 70 percent for 2 hours each time, then the extract is concentrated to 20g, and the corresponding extract is obtained after storage at the temperature of 4 ℃.
Further, the odontogenic stem cell exosome markers are TSG101, CD81 and CD63 proteins.
Further, the preparation method of the tooth source stem cell exosome comprises the following steps:
(1) Inoculating dental pulp stem cells into a culture dish or a culture bottle, discarding old culture medium when the growth of the cells is fused to 80%, washing 3 times by PBS, and adding a basal culture medium;
(2) After culturing for 24-48 hours, collecting the cell culture solution;
(3) DMEM washed with PBS to remove dead cells and replaced with 10% fbs;
(4) Continuously collecting about 500ml of cell culture solution, and sub-packaging into 50ml centrifuge tubes;
centrifuging to remove macromolecular vesicles, concentrating in a 100KD ultrafiltration tube, discarding liquid with a height of 1.5cm from the bottom of the centrifugation tube, and centrifuging at 5000g at 4deg.C for 10min to obtain culture medium concentrate; 5ml of sucrose solution with the volume percentage of 30% is injected into the concentrated culture medium solution, and after layering occurs, the concentrated culture solution is continuously added, so that the liquid level is up to the position of a pipe orifice of 3 mm; centrifuging, removing the upper culture medium, and gently sucking sucrose solution containing exosomes below by using a syringe; and (3) after collecting sucrose solution, diluting with PBS buffer solution, placing into an ultrafiltration tube with 100KD, balancing, repeatedly washing with PBS, centrifuging until removing sucrose heavy water solution, and finally collecting concentrated solution which is an exosome of dental stem cells, filtering, sterilizing, and storing in a refrigerator at-80 ℃.
The invention has the following beneficial effects:
according to the technical scheme, the odontogenic exosome can effectively enhance the bone differentiation of periodontal bone cells, in addition, the pueraria extract and the peppermint extract are screened from a plurality of reported traditional Chinese medicines with the bone differentiation through screening of inducers, and according to the research of clinical cases, the extract can effectively promote the regrowth of cementum wires, increase the bone level and restore bone trabeculae, and after the reasonable proportion of the two inducers, the bone level can be increased to more than 4.0mm, and compared with the prior art, the 3.0mm improvement effect is better, and the effect is better in periodontal bone reconstruction medicines.
[ description of the drawings ]
FIG. 1 is a morphology of a mesenchymal stem cell gel;
FIG. 2 is a morphology of exosomes under electron microscopy;
FIG. 3 is a graph showing the analysis of NTA particle size of exosomes;
FIG. 4 is a graph of Western Blot detection results of exosomes;
fig. 5-12 are x-ray images taken before and after treatment of a partial case.
[ detailed description ] of the invention
The following detailed description of the present invention will provide further details in order to make the above-mentioned objects, features and advantages of the present invention more comprehensible. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. The invention may be embodied in many other forms than described herein and similarly modified by those skilled in the art without departing from the spirit or scope of the invention, which is therefore not limited to the specific embodiments disclosed below.
Example 1:
1. mesenchymal stem cell gel acquisition:
and collecting 10mL of venous peripheral blood, namely putting the peripheral blood into a variable speed centrifuge for centrifugation for three minutes, after the variable speed centrifugation is finished, beating a blood vessel in a sterile operation table, taking out jelly-like PRF, transferring to a disinfection vessel, shearing to remove upper-layer pale yellow colloid, and simply cleaning erythrocytes in the jelly with 5mL of physiological saline to retain the colloid, thereby obtaining mesenchymal stem cell gel, wherein the colloid shape is shown in figure 1.
And (3) carrying out culture increase and substitution transfer by using a special culture medium (purchased from HYCLONE company) for mesenchymal stem cells, and harvesting p 4-generation cells.
After that, immunofluorescent staining was performed, and the mesenchymal stem cell factor protein markers CD73, CD90 and CD105 were positive according to the detection standard of the International cell therapy Union (see, in particular, patent document: 202110311551. X).
2. Obtaining tooth source stem cell exosomes:
obtaining odontogenic stem cells from deciduous teeth and adult corrective tooth extraction of normal infants; the missing teeth are from the normal tooth extraction of the south peace paste, wound and beauty oral outpatient department.
1. Acquisition of odontogenic stem cell exosomes:
(1) Mixing the deciduous dental pulp stem cells of the young children and the adult dental pulp stem cells, inoculating the mixed deciduous dental pulp stem cells into a culture dish or a culture bottle, discarding old culture medium when the growth of the cells is fused to 80%, washing for 3 times by PBS, and adding a basic culture medium;
(2) After culturing for 24-48 hours, collecting the cell culture solution;
(3) DMEM washed with PBS to remove dead cells and replaced with 10% fbs;
(4) Continuously collecting about 500ml of cell culture solution, and sub-packaging into 50ml centrifuge tubes;
(5) Centrifuging to remove macromolecular vesicles, concentrating in a 100KD ultrafilter tube, discarding liquid with a height of 1.5cm from the bottom of the tube, centrifuging at 5000g at 4deg.C for 10min to obtain culture medium concentrate; 5ml of sucrose solution with the volume percentage of 30% is injected into the concentrated culture medium solution, and after layering occurs, the concentrated culture solution is continuously added, so that the liquid level is up to the position of a pipe orifice of 3 mm; centrifuging, removing the upper culture medium, and gently sucking sucrose solution containing exosomes below by using a syringe; and (3) after collecting the sucrose solution, diluting with PBS buffer solution, placing into an ultrafiltration tube with 100KD, balancing, repeatedly washing with PBS, centrifuging until removing sucrose heavy water solution, and finally collecting concentrated solution which is the exosomes derived from odontogenic stem cells, filtering, sterilizing and storing in a refrigerator at-80 ℃.
2. Identification of exosomes
(1) Transmission Electron Microscope (TEM)
The sample was centrifuged, 10. Mu.l of the sample was pipetted onto a copper mesh, and after standing for several minutes, the excess float of the sample was pipetted using filter paper. After 10 μl of phosphotungstic acid is dripped on a copper mesh and dyed for 1min at room temperature, the floating liquid is sucked by filter paper, after drying for a few minutes, the sample is put under a transmission electron microscope for 80kv-120kv imaging, the physical characteristics of vesicles in the sample, including morphology, diameter size and membrane structure, are identified, the identification result is shown in figure 2, and the exosomes have different morphology sizes under the electron microscope and are similar to circles or ellipsoids.
(2) Exosome particle size analysis
And sucking 10 μl of the extracted exosome sample, diluting the sample by using 1 XPBS buffer solution, performing particle size analysis on the exosome, and determining the particle size of the exosome in the sample to further identify the distribution of the exosome. The experimental process temperature was maintained at 23 ℃ to 37 ℃. As a result, as shown in FIG. 3, it was found from the NTA particle size analysis of the exosomes that the exosomes have a particle size distribution concentrated at 50-150nm.
(3) Western Blot Western Blot detection is carried out on the specific protein markers;
the obtained results are shown in figure 4, and the exosome protein markers TSG101, CD81 and CD63 have clear bands and are positive, so that the method can be proved to be capable of effectively obtaining the odontogenic stem cell exosome.
Example 2:
the application of different inducers in periodontal bone reconstruction is adopted in the embodiment, and the specific steps are as follows:
inducer: radix Puerariae extract, herba Epimedii extract, herba Menthae extract and folium Nelumbinis extract.
The preparation method of the inducer extracts comprises the following steps: 500g of dry kudzuvine root, dry epimedium herb, fresh peppermint and fresh lotus leaf medicinal materials are respectively weighed, and are refluxed for 2 times with ethanol solution with the volume percentage of 70 percent for 2 hours each time, then the extract is concentrated to 20g, and the corresponding inducer is obtained after storage at the temperature of 4 ℃.
Then, mesenchymal stem cell gel, a odontogenic stem cell exosome, bone meal and an inducer are adopted to be applied to periodontal bone reconstruction operation of periodontitis, and the specific steps are as follows: surgical site: is carried out in the south peace, close to the mind, and create and beautify the oral clinic department; case sources 2018-2021; the specific surgical groupings are as follows:
CK group: and selecting periodontal bone retraction cases for operation, applying anti-inflammatory drugs after tooth washing and cleaning, and incising the gingiva after the gingiva is red, swollen and disappeared. Putting bone meal, mesenchymal stem cell culture solution and odontogenic stem cell exosome into the suture (30 cases are produced in total); the mass percent of the mesenchymal stem cell gel of the CK group is 15%, the mass percent of the odontogenic stem cell exosome is 5%, and the mass percent of the bone powder is 80%.
Radix Puerariae inducer group: and selecting periodontal bone retraction cases for operation, applying anti-inflammatory drugs after tooth washing and cleaning, and incising the gingiva after the gingiva is red, swollen and disappeared. Putting bone meal, mesenchymal stem cell culture solution, odontogenic stem cell exosomes and radix puerariae extract into the mixture for stitching (30 cases are taken as a total);
epimedium inducer group: and selecting periodontal bone retraction cases for operation, applying anti-inflammatory drugs after tooth washing and cleaning, and incising the gingiva after the gingiva is red, swollen and disappeared. Putting bone meal, mesenchymal stem cell culture solution, odontogenic stem cell exosomes and epimedium extract into the mixture for stitching (30 cases are taken together);
mint inducer group: and selecting periodontal bone retraction cases for operation, applying anti-inflammatory drugs after tooth washing and cleaning, and incising the gingiva after the gingiva is red, swollen and disappeared. Putting bone meal, mesenchymal stem cell culture solution, odontogenic stem cell exosomes and mint extract into the mixture for stitching (30 cases are taken as a total);
lotus leaf inducer group: and selecting periodontal bone retraction cases for operation, applying anti-inflammatory drugs after tooth washing and cleaning, and incising the gingiva after the gingiva is red, swollen and disappeared. Putting bone powder, mesenchymal stem cell culture solution, odontogenic stem cell exosome and lotus leaf extract, and stitching (30 cases are taken together).
In this example, the mass percentage of mesenchymal stem cell gel of each inducer was 15%, the mass percentage of odontogenic stem cell exosomes was 4%, the mass percentage of bone meal was 80% and the mass percentage of inducer was 1%.
The patient's x-ray film was photographed 6 months after surgery, the heightened bones were measured, the results were both represented by positive and negative standard deviations of the mean, statistical analysis was performed with spss21.0, and significance analysis was performed as needed. The results obtained are shown in Table 1:
TABLE 1 Effect of different inducers on tooth Zhou Gutou increase
Test item | CK group | Radix Puerariae inducer | Epimedium inducer | Mint inducer | Nelumbo nucifera leaf inducer |
Heightening (mm) | 2.33±0.11 a | 3.01±0.31 b | 2.35±0.20 a | 3.46±0.21 c | 2.26±0.18 a |
Note that: english a, b, c indicate statistically significant differences (P < 0.05) in the same row comparison.
As can be seen from table 1, the heights of the periodontal bone increases of the epimedium inducer and the lotus leaf inducer are not greatly different from those of the CK group, the differences are not obvious, while Gao Duyuan of the periodontal bone increases of the kudzu root inducer and the peppermint inducer are higher than those of the CK group, and obvious differences are achieved, so that the growth is promoted more effectively, and therefore, not all traditional Chinese medicine inducers can promote the growth of the periodontal bone; the height of periodontal bone increase of the peppermint inducer is higher than that of the kudzu root inducer group, and a significant difference is achieved.
In view of the above results, the applicant has further studied using radix Puerariae and folium Nelumbinis to formulate an inducer, specifically as follows:
surgical site: is carried out in the south peace, close to the mind, and create and beautify the oral clinic department; case sources 2021-2022; the specific operation grouping method is as follows: the periodontal bone recession cases were selected for surgery, after tooth washing and cleaning, anti-inflammatory drugs were applied, the gums were incised and the drugs as shown in Table 2 were placed and then sutured (30 cases were applied to each group) until the gum red swelling disappeared.
Table 2 pharmaceutical combinations of inducers in different ratios
The patient's x-ray film was photographed 6 months after surgery, the heightened bones were measured, the results were both represented by positive and negative standard deviations of the mean, statistical analysis was performed with spss21.0, and significance analysis was performed as needed. The results obtained are shown in Table 3:
TABLE 3 Effect of different drugs on tooth Zhou Gutou increase
Test item | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
Heightening (mm) | 3.13±0.01 a | 3.10±0.22 a | 4.18±0.17 b | 3.08±0.15 a | 3.05±0.18 a |
Note that: english a, b indicates that the same row comparison has statistically significant differences (P < 0.05).
As can be seen from table 3, the effect of the root of kudzu vine inducer and the mint inducer on periodontal bone elevation was best significantly higher (best) than that of the single-thin-charge inducer of table 2 when the mass ratio of the root of kudzu vine inducer to the mint inducer was 1:3, while the other mass ratios were slightly higher than Shan Gegen inducer than that of the single inducer, indicating that the root of kudzu vine inducer and the mint inducer had significant effects only when the mass ratio was 1:3 when used in combination, and the effect of the other mass ratios on bone elevation was not great.
The above study results show that: although it is reported in the prior art that the traditional Chinese medicine preparation can promote osteogenic differentiation as an inducer, in the practical application process, bone growth is not necessarily promoted, and it is possible that the components in the traditional Chinese medicine preparation have the effect of promoting osteogenic differentiation and inhibiting cell growth, and the dosage is required to be strictly controlled; it is also possible that some traditional Chinese medicine agents, although promoting osteogenic differentiation, may not have an effective anti-inflammatory and cell differentiation promoting effect on specific conditions in indications of periodontitis.
The bone meal of the application is purchased from south Beijing, yiterbo medical science and technology development Co.
The x-ray images of some cases of the present application are shown in fig. 5-12:
case 1:
zhang Jie 64, periodontitis is diagnosed at hospital arrival; at the time of day 12 and 8 of 2021, the teeth were photographed as shown in fig. 4, and after surgery and treatment with the bone reconstruction drug of example 2 group 3, the teeth were photographed as shown in fig. 5 after 6 months; the dental film showed a 4.0mm increase in periodontal bone.
Case 2:
zheng Weixiong 73 years old, periodontitis was diagnosed at hospital arrival; at the time of day 1 and 2 of 2022, the patient had a dental film as shown in fig. 6, and after surgery and treatment with the bone reconstruction drug of example 2 group 3, the patient had a dental film as shown in fig. 7 after 6 months; the dental film showed 3.9mm increase in periodontal bone.
Case 3:
the 45-year old Zhiti is diagnosed as periodontitis when the hospital comes; at the time of 20 days of 2021, 10 months, the doctor took the teeth as shown in fig. 8, and 6 months after surgery and the addition of the bone reconstruction drug of example 2 group 3, the doctor took the teeth as shown in fig. 9; the dental film showed a 4.1mm increase in periodontal bone.
Case 4:
li Zhiyang 47 years old, periodontitis was diagnosed at hospital arrival; at the time of day 4 and 10 of 2021, the teeth were photographed as shown in the left panel of fig. 10, and after surgery and the addition of the bone reconstruction drug of example 2 group 3, the teeth were photographed as shown in the right panel of fig. 10 after 6 months; the dental film showed a 4.2mm increase in periodontal bone.
Case 5:
yu Guo 40, periodontitis is diagnosed at hospital arrival; at the time of day 3 of 6 of 2021, the teeth were photographed as shown in the left panel of fig. 11, and after surgery and the addition of the bone reconstruction drug of example 2 group 3, the teeth were photographed as shown in the right panel of fig. 11 after 6 months; the dental film showed a 4.2mm increase in periodontal bone.
Example 3:
the influence of exosomes on periodontal bone remodeling was studied in this example, as follows:
periodontal bone reconstruction procedures are performed by the method disclosed in reference 202110311551.X, as follows
CK group: and selecting periodontal bone retraction cases for operation, applying anti-inflammatory drugs after tooth washing and cleaning, and incising the gingiva after the gingiva is red, swollen and disappeared. Placing mesenchymal stem cell gel 19%, bone powder 80% and inducer 1% for suturing (20 cases are taken together); wherein the inducer is radix Puerariae extract (the preparation method of the extract is shown in example 2);
exosome group: and selecting periodontal bone retraction cases for operation, applying anti-inflammatory drugs after tooth washing and cleaning, and incising the gingiva after the gingiva is red, swollen and disappeared. Placing 15% of mesenchymal stem cell gel, 4% of odontogenic stem cell exosome, 80% of bone meal and 1% of inducer for suturing (20 cases are produced); wherein the inducer is radix Puerariae extract (the preparation method of the extract is shown in example 2)
The patient's x-ray film was photographed 6 months after surgery, the heightened bones were measured, the results were both represented by positive and negative standard deviations of the mean, statistical analysis was performed with spss21.0, and significance analysis was performed as needed. The results obtained are shown in Table 4:
TABLE 4 influence of exosomes on tooth Zhou Gutou increase
Test item | CK group | Exosome group |
Heightening (mm) | 2.54±0.11 a | 3.10±0.02 b |
Note that: english a, b indicates that the same row comparison has statistically significant differences (P < 0.05).
From the above table, the bone elevation effect of periodontal bone is better than that of the control group without exosomes after exosomes are added, which indicates that the odontogenic exosomes have the effect of promoting bone differentiation and can promote the bone formation of periodontal bone; the bone-increasing effect of the CK group was slightly lower than that of patent 202110311551.X, indicating that bone-meal content was also a factor affecting periodontal bone formation.
From the comprehensive examples 1-3, the optimum formulation of the drug for promoting periodontal bone remodeling is as follows: 15% of mesenchymal stem cell gel, 4% of odontogenic stem cell exosomes, 80% of bone meal and 1% of inducer; wherein the inducer is prepared by mixing radix Puerariae extract and herba Menthae extract at a mass ratio of 1:3.
(1) Inoculating dental pulp stem cells into a culture dish or a culture bottle, discarding old culture medium when the growth of the cells is fused to 80%, washing 3 times by PBS, and adding a basal culture medium;
(2) After culturing for 24-48 hours, collecting the cell culture solution;
(3) DMEM washed with PBS to remove dead cells and replaced with 10% fbs;
(4) Continuously collecting about 500ml of cell culture solution, and sub-packaging into 50ml centrifuge tubes;
centrifuging to remove macromolecular vesicles, concentrating in a 100KD ultrafiltration tube, discarding liquid with a height of 1.5cm from the bottom of the centrifugation tube, and centrifuging at 5000g at 4deg.C for 10min to obtain culture medium concentrate; 5ml of sucrose solution with the volume percentage of 30% is injected into the concentrated culture medium solution, and after layering occurs, the concentrated culture solution is continuously added, so that the liquid level is up to the position of a pipe orifice of 3 mm; centrifuging, removing the upper culture medium, and gently sucking sucrose solution containing exosomes below by using a syringe; and (3) after collecting sucrose solution, diluting with PBS buffer solution, placing into an ultrafiltration tube with 100KD, balancing, repeatedly washing with PBS, centrifuging until removing sucrose heavy water solution, and finally collecting concentrated solution which is an exosome of dental stem cells, filtering, sterilizing, and storing in a refrigerator at-80 ℃.
In summary, compared with the prior art, the medicine can effectively reconstruct periodontal bones, and deep research on inducers shows that: the kudzu root extract and the mint extract can be used as inducers to improve the reconstruction effect on periodontal bones.
The above examples only represent a few embodiments of the present invention, which are described in more detail and are not to be construed as limiting the scope of the present invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of the invention should be assessed as that of the appended claims.
Claims (7)
1. A medicament for promoting periodontal bone reconstruction by utilizing stem cell exosomes, which is characterized by comprising the following components in percentage by mass: 15% of mesenchymal stem cell gel, 4% of odontogenic stem cell exosomes, 80% of bone meal and 1% of inducer; the inducer is radix Puerariae extract and/or herba Menthae extract.
2. The medicine for promoting periodontal bone reconstruction by utilizing stem cell exosomes according to claim 1, wherein the pueraria extract and the peppermint extract are ethanol extracts.
3. A medicament for promoting periodontal bone remodeling using stem cell exosomes according to claim 2, wherein the ethanol of the ethanol extract is 70% ethanol solution by volume.
4. The medicine for promoting periodontal bone reconstruction by utilizing stem cell exosomes according to claim 1, wherein the mass ratio of the pueraria extract to the peppermint extract is 1:3.
5. The medicine for promoting periodontal bone reconstruction by utilizing stem cell exosomes according to claim 2, wherein the specific extraction method of the kudzuvine root extract and the peppermint extract is as follows: 500g of dried kudzuvine root and fresh peppermint are respectively weighed, and are refluxed for 2 times by using 70 percent ethanol solution for 2 hours each time, then the extract is concentrated to 20g, and the corresponding extract is obtained after being stored at the temperature of 4 ℃.
6. A medicament for promoting periodontal bone remodeling using stem cell exosomes according to claim 1, wherein the odontogenic stem cell exosomes markers are TSG101, CD81 and CD63 proteins.
7. A medicament for promoting periodontal bone remodeling using stem cell exosomes according to claim 1, wherein the preparation method of the odontogenic stem cell exosomes is as follows:
(1) Inoculating dental pulp stem cells into a culture dish or a culture bottle, discarding old culture medium when the growth of the cells is fused to 80%, washing 3 times by PBS, and adding a basal culture medium;
(2) After culturing for 24-48 hours, collecting the cell culture solution;
(3) DMEM washed with PBS to remove dead cells and replaced with 10% fbs;
(4) Continuously collecting about 500ml of cell culture solution, and sub-packaging into 50ml centrifuge tubes;
(5) Centrifuging to remove macromolecular vesicles, concentrating in a 100KD ultrafiltration tube, discarding liquid with a height of 1.5cm from the bottom of the centrifugation tube, and centrifuging at 5000g at 4deg.C for 10min to obtain culture medium concentrate; 5ml of sucrose solution with the volume percentage of 30% is injected into the concentrated culture medium solution, and after layering occurs, the concentrated culture solution is continuously added, so that the liquid level is up to the position of a pipe orifice of 3 mm; centrifuging, removing the upper culture medium, and gently sucking sucrose solution containing exosomes below by using a syringe; and (3) after collecting sucrose solution, diluting with PBS buffer solution, placing into an ultrafiltration tube with 100KD, balancing, repeatedly washing with PBS, centrifuging until removing sucrose heavy water solution, and finally collecting concentrated solution which is an exosome of dental stem cells, filtering, sterilizing, and storing in a refrigerator at-80 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310359219.XA CN116350676B (en) | 2023-04-06 | 2023-04-06 | Medicine for promoting periodontal bone reconstruction by stem cell exosome |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310359219.XA CN116350676B (en) | 2023-04-06 | 2023-04-06 | Medicine for promoting periodontal bone reconstruction by stem cell exosome |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116350676A true CN116350676A (en) | 2023-06-30 |
CN116350676B CN116350676B (en) | 2023-11-28 |
Family
ID=86931788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310359219.XA Active CN116350676B (en) | 2023-04-06 | 2023-04-06 | Medicine for promoting periodontal bone reconstruction by stem cell exosome |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116350676B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010260794A (en) * | 2009-04-30 | 2010-11-18 | Lion Corp | Alveolar bone absorption inhibitor |
CN102625866A (en) * | 2009-04-01 | 2012-08-01 | 高露洁-棕榄公司 | Menthol-derivative compounds and use thereof as oral and systemic active agents |
CN112843339A (en) * | 2021-03-24 | 2021-05-28 | 吴涛 | Application of mesenchymal stem cells in preparation of periodontal bone reconstruction medicine |
-
2023
- 2023-04-06 CN CN202310359219.XA patent/CN116350676B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102625866A (en) * | 2009-04-01 | 2012-08-01 | 高露洁-棕榄公司 | Menthol-derivative compounds and use thereof as oral and systemic active agents |
JP2010260794A (en) * | 2009-04-30 | 2010-11-18 | Lion Corp | Alveolar bone absorption inhibitor |
CN112843339A (en) * | 2021-03-24 | 2021-05-28 | 吴涛 | Application of mesenchymal stem cells in preparation of periodontal bone reconstruction medicine |
Non-Patent Citations (2)
Title |
---|
金珊丹等: "葛根素在兔牙周组织改建中的作用", 中国组织工程研究, vol. 16, no. 42, pages 7853 * |
魏继珍: "人脱落乳牙牙髓干细胞来源外泌体调节骨髓间充质干细胞生物学特性及其在骨缺损修复中的研究", 中国优秀硕士学位论文全文数据库, no. 10, pages 3 * |
Also Published As
Publication number | Publication date |
---|---|
CN116350676B (en) | 2023-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021103581A1 (en) | Skin topical composition having efficacy of promoting wound healing and/or scar repair | |
CN111748520B (en) | Tooth sac stem cell exosome, preparation method and application thereof, composition thereof and preparation method | |
CN101766656A (en) | Combination containing mushroom polysaccharide and preparation method thereof | |
CN112755052A (en) | Application of human deciduous tooth pulp stem cell exosome | |
CN113713067B (en) | Traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis and preparation method thereof | |
CN116350676B (en) | Medicine for promoting periodontal bone reconstruction by stem cell exosome | |
CN103040910A (en) | Cervus and cucumis polypeptide liposome injection | |
CN103191418B (en) | Buccal patch for treating dental ulcer by combination of internal and external treatments | |
CN101156849B (en) | An alepsin slow-releasing gel for promoting paradontal part reborn as well as preparation method and application | |
Hanafiah et al. | Formulation and evaluation of binahong leaves extract gel on wound healing of the palatal mucosa | |
CN113952498A (en) | Chinese medicine multi-component liquid wound healing dressing and preparation method thereof | |
WO2000078324A1 (en) | The leaves of cajanus cajan(l.) millsp and extract, formulation and uses thereof | |
JP2022551319A (en) | American cockroach extract, formulation, preparation method and use thereof | |
CN116492369B (en) | Traditional Chinese medicine polysaccharide composition with anti-inflammatory and hemostatic effects and application thereof | |
CN105878418B (en) | Hair growth medicinal composition and preparation method thereof | |
CN114028239B (en) | Root canal disinfection paste and preparation method thereof | |
CN114470174B (en) | Composition for preventing and treating osteoporosis | |
Wulandari et al. | Effectiveness of Kirinyuh (Chromolaena Odorata) Extract on Increasing of Collagen Fibers after Tooth Extraction | |
CN117338847A (en) | Application of morinda officinalis-derived extracellular vesicle-like nano particles in preparation of medicines for preventing or treating orthopedic diseases | |
US20240269195A1 (en) | Compositions and methods relating to pooled fetal support tissue | |
CN106267166A (en) | A kind of dental pulp regeneration paste and preparation method thereof | |
CN115634262A (en) | Anti-inflammatory composition and application and preparation method thereof | |
CN118620098A (en) | Application of roxburgh rose polysaccharide in preparing medicine for resisting vascular calcification | |
Bramantia et al. | Effectivity of Camellia sinensisExtract with Nano-chitosan to Fibroblast Amounts of Wistar Rats Gingival Wound Healing Process | |
RU2578429C2 (en) | Beauty mask for face |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |